Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Rottinghaus

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Expert Review of Anti-Infective Therapy|April 4, 2007
Current non-AIDS antiviral chemotherapyScott T Rottinghaus, Richard J Whitley
Clinical and Translational Science|April 28, 2025
EDP-323, a First-In-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy AdultsKimberly Elmore, John DeVincenzo, Michael H J Rhodin, et al.
Vaccine|October 25, 2003
Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccinationScott T Rottinghaus, Gregory A Poland, Robert M Jacobson, et al.
Vaccine|August 21, 2007
HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in miceScott D Parker, Scott T Rottinghaus, Allan J Zajac, et al.
International Journal of Antimicrobial Agents|July 9, 2015
Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trialsMatteo Bassetti, Paul C McGovern, Christoph Wenisch, et al.
Journal of the American Academy of Dermatology|October 30, 2017
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatmentKevin L Winthrop, Neil Korman, William Abramovits, et al.
Therapeutic Advances in Hematology|November 12, 2020
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized studyHubert Schrezenmeier, Austin Kulasekararaj, Lindsay Mitchell, et al.
Patient Preference and Adherence|April 21, 2020
Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ<sup>©</sup>)Karen Kaiser, Susan E Yount, Christa E Martens, et al.
Journal of the American Academy of Dermatology|July 17, 2017
Herpes zoster in psoriasis patients treated with tofacitinibKevin L Winthrop, Mark Lebwohl, Arnon D Cohen, et al.
Blood|December 5, 2018
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 studyJong Wook Lee, Flore Sicre de Fontbrune, Lily Wong Lee Lee, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Expert Review of Anti-Infective Therapy|April 4, 2007
Current non-AIDS antiviral chemotherapyScott T Rottinghaus, Richard J Whitley
Clinical and Translational Science|April 28, 2025
EDP-323, a First-In-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy AdultsKimberly Elmore, John DeVincenzo, Michael H J Rhodin, et al.
Vaccine|October 25, 2003
Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccinationScott T Rottinghaus, Gregory A Poland, Robert M Jacobson, et al.
Vaccine|August 21, 2007
HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in miceScott D Parker, Scott T Rottinghaus, Allan J Zajac, et al.
International Journal of Antimicrobial Agents|July 9, 2015
Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trialsMatteo Bassetti, Paul C McGovern, Christoph Wenisch, et al.
Journal of the American Academy of Dermatology|October 30, 2017
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatmentKevin L Winthrop, Neil Korman, William Abramovits, et al.
Therapeutic Advances in Hematology|November 12, 2020
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized studyHubert Schrezenmeier, Austin Kulasekararaj, Lindsay Mitchell, et al.
Patient Preference and Adherence|April 21, 2020
Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ<sup>©</sup>)Karen Kaiser, Susan E Yount, Christa E Martens, et al.
Journal of the American Academy of Dermatology|July 17, 2017
Herpes zoster in psoriasis patients treated with tofacitinibKevin L Winthrop, Mark Lebwohl, Arnon D Cohen, et al.
Blood|December 5, 2018
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 studyJong Wook Lee, Flore Sicre de Fontbrune, Lily Wong Lee Lee, et al.
Pageof 2